Curevo Vaccine

Curevo Vaccine is a high-potential, clinical-stage biotechnology company with over $190M in verifiable funding (Series B) and positive Phase 2 data for its shingles vaccine, CRV-101. While the project itself demonstrates exceptional real-world utility and market relevance as a competitor to Shingrix, the submission quality is critically poor, containing false claims about user adoption ('most people have used my product') and irrelevant tags ('software-development'). The score reflects the massive verifiable value of the entity, heavily penalized for the low-quality and inaccurate submission data.